
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
AI Summary
- About
LMF Acquisition Opportunities Inc (ICUCW)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
02/20/2025: ICUCW (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Analysis of Past Performance
Type Stock | Historic Profit -34.62% | Avg. Invested days 23 | Today’s Advisory WEAK BUY |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) 45861 | Beta -0.99 | 52 Weeks Range 0.01 - 0.24 | Updated Date 02/17/2025 |
52 Weeks Range 0.01 - 0.24 | Updated Date 02/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -6552.94% |
Management Effectiveness
Return on Assets (TTM) -292.92% | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 4384909 |
Shares Outstanding - | Shares Floating 4384909 | ||
Percent Insiders - | Percent Institutions - |
AI Summary
LMF Acquisition Opportunities Inc. (NASDAQ: LMF.U) - Comprehensive Overview
Company Profile:
History and Background: LMF Acquisition Opportunities Inc. is a blank check company formed in February 2021 for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.
Core Business Areas: As a SPAC (Special Purpose Acquisition Company), LMF doesn't have any existing business operations. Its primary focus is to identify and acquire a target company within a specified timeframe. The company's target industry is not specified, leaving it open to potential acquisitions across various sectors.
Leadership Team and Corporate Structure:
- CEO and Chairman: Luis Medina
- CFO and Treasurer: Kevin J. Smith
- Executive Vice President and Secretary: Daniel R. McClary
The company's board of directors consists of five members, including Luis Medina, Andrew T. Cohen, Robert W. Grady, Richard S. Kramer, and Thomas J. Wilson.
Top Products and Market Share:
LMF Acquisition Opportunities Inc. does not have any products or services, as it is a pre-acquisition company.
Total Addressable Market:
As the company hasn't yet acquired a target, its total addressable market is undefined. However, considering its focus on technology-related businesses, the potential market size could be substantial.
Financial Performance:
LMF has not generated any revenue or earnings as it is a pre-revenue company.
Dividends and Shareholder Returns:
Since the company hasn't commenced operations, it hasn't paid any dividends or generated any shareholder returns.
Growth Trajectory:
LMF's growth trajectory will depend on the target company it acquires. The company's future success will be determined by the performance of the acquired business and its ability to capitalize on market opportunities.
Market Dynamics:
The SPAC market is experiencing a slowdown after a period of rapid growth. However, there is still significant interest from investors in quality SPACs with strong management teams and promising acquisition targets.
Competitors:
LMF competes with other SPACs looking to acquire technology-related businesses.
Key Competitors:
- CIIC Merger Corp. (CIIC)
- GO Acquisition Corp. (GOAC)
- Social Capital Hedosophia Holdings VI (IPOF)
Recent Acquisitions:
LMF has not completed any acquisitions to date.
AI-Based Fundamental Rating:
Based on publicly available information, it is not possible to provide an AI-based fundamental rating for LMF. Such a rating would require detailed analysis of the company's financial statements, management team, and potential acquisition targets, which are currently unavailable.
Sources and Disclaimers:
This analysis is based on information obtained from LMF Acquisition Opportunities Inc.'s SEC filings and press releases. Investors should conduct their own due diligence before making any investment decisions.
Disclaimer:
This information is provided for educational purposes only and should not be considered as financial advice.
Please note: This analysis is based on publicly available information as of today's date, October 26, 2023. Any information published after this date may not be reflected in this analysis.
About LMF Acquisition Opportunities Inc
Exchange NASDAQ | Headquaters Denver, CO, United States | ||
IPO Launch date 2021-03-18 | CEO, President & Executive Director Mr. Eric Schlorff | ||
Sector Healthcare | Industry Biotechnology | Full time employees 12 | Website https://www.seastarmedical.com |
Full time employees 12 | Website https://www.seastarmedical.com |
SeaStar Medical Holding Corporation, a medical device company, develops a platform therapy to reduce the consequences of hyperinflammation on vital organs in the United States. The company offers inflammatory response to fend off infections and repair damaged tissue in the body. It is also developing products in various therapeutic areas, including pediatric and adult acute kidney injury on CRRT; cardiorenal syndrome in congestive heart failure; myocardial stunning in end stage renal disease; and hepatorenal syndrome. The company is headquartered in Denver, Colorado.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.